Heron Therapeutics Inc vs Plug Power Inc — how do they compare? Heron Therapeutics Inc trades at $0.47 (market cap $91.46M), while Plug Power Inc trades at $2.24 (market cap $2.98B). The key difference: Plug Power Inc is far larger — about 32.6× Heron Therapeutics Inc's market cap, and Plug Power Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | PLUG | |
|---|---|---|
Market Cap | $91.46M | $2.98B |
Sector | Health | Industrials |
52-Week High | $1.96 | $4.14 |
52-Week Low | $0.39 | $1.40 |
Enterprise Value | $189.36M | $3.77B |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
Plug Power (PLUG) trades at $2.14, down 0.47% on the day, reflecting ongoing investor concerns about profitability despite recent contract wins. The stock shows bearish technical signals with negative moving averages, while fundamentals reveal persistent losses with a -227.13% net income margin and negative cash flow. Recent news highlights a major 50MW Australian hydrogen project win, but operational challenges and dilution risks remain.
The outlook remains challenging with significant execution risks and cash burn, though analyst consensus suggests 36% upside to the $2.92 price target. Investment opportunity hinges on hydrogen adoption scaling faster than losses, while key risks include continued dilution, competitive pressure, and the company's ability to achieve profitability amid high debt levels.
Trailing returns across standard periods
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →